TENX — Tenax Therapeutics Share Price
0.000.00%
Last trade - 00:00- $23.92m
- -$70.93m
- 25
- 55
- 90
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.26 | ||
| Price to Tang. Book | 0.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.19% | ||
| Return on Equity | -35.17% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Directors
- Gerald Proehl NEC (62)
- Christopher Giordano PRE (47)
- Eliot Lurier CFO (63)
- Stuart Rich OTH (71)
- June Almenoff IND (64)
- Steven Boyd IND (40)
- Michael Davidson IND (64)
- Delcan Doogan IND (69)
- Robyn Hunter IND (60)
- I. Keith Maher IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 17th, 2008
- Public Since
- October 28th, 1993
- No. of Shareholders
- 1,337
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 4,148,495
- Address
- 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, 27517
- Web
- http://www.tenaxthera.com/
- Phone
- +1 9198552100
- Auditors
- Cherry Bekaert LLP
Upcoming Events for TENX
Tenax Therapeutics Inc Annual Shareholders Meeting
Tenax Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Tenax Therapeutics Inc Earnings Release
Similar to TENX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Tenax Therapeutics share price?
As of Today at 23:38 UTC, shares in Tenax Therapeutics are trading at $5.77. This share price information is delayed by 15 minutes.
How has the Tenax Therapeutics share price performed this year?
Shares in Tenax Therapeutics last closed at $5.77 and the price had moved by +52.11% over the past 365 days. In terms of relative price strength the Tenax Therapeutics share price has outperformed the S&P500 Index by +37.16% over the past year.
What are the analyst and broker recommendations for Tenax Therapeutics?
The overall consensus recommendation for Tenax Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tenax Therapeutics dividend yield?
Tenax Therapeutics does not currently pay a dividend.
Does Tenax Therapeutics pay a dividend?
Tenax Therapeutics does not currently pay a dividend.
When does Tenax Therapeutics next pay dividends?
Tenax Therapeutics does not currently pay a dividend.
How do I buy Tenax Therapeutics shares?
To buy shares in Tenax Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tenax Therapeutics?
As of the previous close price of $5.77, shares in Tenax Therapeutics had a market capitalisation of $23.92m.
Where are Tenax Therapeutics shares listed?
Here are the trading details for Tenax Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TENX
What kind of share is Tenax Therapeutics?
Based on an overall assessment of its quality, value and momentum Tenax Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tenax Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Tenax Therapeutics is $22.00. That is 281.61% above the last closing price of $5.77.
Analysts covering Tenax Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.86 for the next financial year.
Find out moreWhat is the trend in the Tenax Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tenax Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +29.13%.
As of the last closing price of $5.77, shares in Tenax Therapeutics were trading +12.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tenax Therapeutics PE Ratio?
The Tenax Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tenax Therapeutics?
Tenax Therapeutics' management team is headed by:
- Gerald Proehl - NEC
- Christopher Giordano - PRE
- Eliot Lurier - CFO
- Stuart Rich - OTH
- June Almenoff - IND
- Steven Boyd - IND
- Michael Davidson - IND
- Delcan Doogan - IND
- Robyn Hunter - IND
- I. Keith Maher - IND